39 patents
Utility
Methods of Manufacture of R-mdma
11 Jan 24
A method of manufacturing R-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with S-propylene oxide to form chirally pure alcohol 1, activating the alcohol as mesylate 2, converting to chirally pure azide 3, reducing the azide to amine 4, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 5 to yield R-MDMA free base 6, and treating with an acid to form a salt 7 in >99% e.e.
Stephen E. SCHNEIDER, Derek LONDESBROUGH
Filed: 29 Jun 23
Utility
Lysergic Acid Derivatives with Modified Lsd-like Action
28 Dec 23
A composition of a compound represented generically by FIG. 1A for use in substance-assisted therapy.
Daniel TRACHSEL, Matthias Emanuel Liechti, Felix Lustenberger
Filed: 19 Jun 23
Utility
R-mdma Crystal Forms
28 Dec 23
A composition of a crystalline form salt or polymorph of R-MDMA.
Stephen E. SCHNEIDER, Gillian MOORE, Julian Scott NORTHEN
Filed: 30 May 23
Utility
Mdma Prodrugs to Assist Psychotherapy
9 Nov 23
A compound including a prodrug having a psychoactive base substance attached to an amino acid.
Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
Filed: 16 May 23
Utility
Method of Titrating Dose of Psychedelics
2 Nov 23
A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances.
Robert Barrow, Daniel R. Karlin
Filed: 1 May 22
Utility
Mdma Enantiomers
5 Oct 23
A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA.
Robert BARROW, Daniel R. Karlin, Gennady N. Smagin
Filed: 8 Jun 23
Utility
Movement Disorders
28 Sep 23
A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
Robert BARROW, Daniel R. KARLIN, Gennady SMAGIN
Filed: 16 May 23
Utility
18-MC Salt Forms
28 Sep 23
A composition including a salt of 18-MC, wherein the salt is chosen from gentisate, hydrobromide, besylate, napadisylate, hydrochloride, sulfate, oxalate, maleate, mesylate, and tosylate.
Jeanne BONELLE, Daniel Emil LEVY, Ann NEWMAN, Stephen E. SCHNEIDER
Filed: 1 Mar 23
Utility
Desoxyscaline Derivatives with Modified Mescaline-like Action
14 Sep 23
A composition of a compound represented by FIG. 1 for use in substance-assisted therapy.
Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
Filed: 12 May 23
Utility
Formulations of Psilocin That Have Enhanced Stability
14 Sep 23
A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability.
Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES
Filed: 31 May 23
Utility
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
14 Sep 23
A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet.
Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY
Filed: 18 May 23
Utility
Mdma Prodrugs to Assist Psychotherapy
27 Jul 23
A compound including a prodrug having a psychoactive base substance attached to an amino acid.
Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
Filed: 28 Mar 23
Utility
Mdma Enantiomers
20 Jul 23
Robert BARROW, Daniel R. KARLIN
Filed: 20 Mar 23
Utility
Mdma Enantiomers
20 Jul 23
A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA.
Robert BARROW, Daniel R. KARLIN
Filed: 20 Mar 23
Utility
Mescaline Derivatives with Modified Action
20 Jul 23
A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R′ is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1 - C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Zallylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.
Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
Filed: 27 Mar 23
Utility
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
13 Jul 23
A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet.
Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
Filed: 3 Apr 23
Utility
18-MC for Treatment of Substance Use Disorders
29 Jun 23
A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier.
Scott FREEMAN, Stots B. REELE, Jeanne BONELLE
Filed: 24 Feb 23
Utility
Desoxyscaline Derivatives with Modified Mescaline-like Action
18 May 23
A composition of a compound represented by FIG. 1 for use in substance-assisted therapy.
Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
Filed: 16 Nov 22
Utility
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
20 Apr 23
A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet.
Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT
Filed: 7 Dec 22
Utility
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
6 Apr 23
A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet.
Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY
Filed: 7 Dec 22